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Abstract  
 
Novel derivatives of the anti-HIV-1 agent, TSAO-T, bearing at the N-3 position alkylating groups or photoaffinity labels were 
prepared and evaluated for their anti-HIV activity. All of these compounds demonstrated pronounced anti-HIV-1 activity and 
inhibited HIV-1 RT; however, we were unable to detect stable covalent linkages between inhibitor and enzyme. In addition, 
compounds with an alcohol functional group connected to the N-3 position through a cis or trans double bond have been prepared. 
These compounds have been useful to study how the conformational restriction of the linker affects in the interaction between the 
N-3 substituent and the HIV-1 RT enzyme. 
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Introduction 
Human immunodeficiency virus (HIV) reverse transcriptase (RT) is an attractive target for the development of anti-AIDS drugs.1-3 
This enzyme plays a multifunctional role in the conversion of the ssRNA viral genome to dsDNA. HIV-1 RT is an asymmetric 
heterodimer which contains two subunits of 66 and 51 kDa designated as p66 and p51, respectively.4-6 The larger subunit (p66) 
contains both polymerase and RNase H activities, while the smaller subunit (p51) lacks these funtions.4-6 The catalytic activity of 
the RT is only observed when it is in its (hetero)dimeric form.7-9 
TSAO-T (Figure 1) is the prototype of a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs).10-13 TSAO 
derivatives are highly functionalised nucleosides, which have a structure and a mechanism of action quite distinct from conventional 
NNRTIs.12 Experimental data on TSAO derivatives strongly suggest a specific interaction of the amino group of the 3’-spiro 
moiety with the carboxylic acid group of a glutamic acid residue at position 138 of the p51 subunit of HIV-1 RT.14-17 This residue  
is lo -
optimal interaction of TSAO derivatives with HIV-1 RT.20 So, TSAO compounds are among the very few RT inhibitors for which 
amino acids at both HIV-1 RT subunits (p51 and p66) are needed for optimal interaction with the enzyme.  
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Fig. 1. Structure of TSAO-T and TSAO-hp3T 
 
Since the first TSAO derivatives were synthesized many efforts to co-crystallize these molecules with their target enzyme (HIV-1 
RT) were pursued. Unfortunately, they have been unsuccessful so far. In 2001, computational docking studies led us to propose a 
putative binding mode of the N-3 methyl derivative of TSAO-T (TSAO-m3T) with HIV-1 RT.21  
The molecular model was in agreement with known structure-activity and mutagenesis data for this unique class of inhibitors, and 
also with biochemical evidence indicating that TSAO molecules can affect enzyme dimerization.22 In fact, the model provided 
strong evidence that TSAO-m3T straddles between both subunits at the p66/p51 interface but in a manner that does not make use of 
the NNRTI binding pocket.  
For the purpose of getting more information about the binding site of TSAO molecules we report herein the synthesis and antiviral 
evaluation of novel TSAO derivatives with alkylating groups or photoaffinity labels that were designed to form covalent interactions 
with HIV-1 RT. As the anchoring point of these moieties we chose the N-3 position of thymine since, as shown by our previous 
biological results,  several compounds modified at this position showed anti HIV-1 activity comparable or even higher than those 
found for TSAO-T.13,23 On the other hand, our docking model indicates that the N-3 substituent at the thymine base of TSAO-m3T 
was found running parallel to the subunit interface and that the presence of functional groups at this position might provide 
additional interactions with amino acids at or near the p51/p66 interface.23 
As some of the amino acids found at the dimer interface near the TSAO binding site have side chains with nucleophilic functional 
groups (Glu-A169, Thr-A165, Lys-B49), we have first prepared TSAO derivatives bearing at the N-3 position of thymine strong 
electrophilic moieties such as an epoxide or a nitrogen mustard with a reactive N,N-bis-(2-chloroethyl)amine group.The alkylating 
properties of these groups might lead to the formation of a covalent bond between the novel TSAO derivatives and the amino acids 
of the HIV-1 RT that might persistently disturb the enzyme and facilitate the location of the inhibitor binding site. 
Second, we prepared photoaffinity labeled TSAO derivatives. These TSAO molecules retain the structural motifs necessary for 
binding with the RT and incorporate at the N-3 position a photoreactive moiety, such as aryl azide and benzophenone. These 
compounds would first selectively interact with the HIV-1 RT and then, upon irradiation with an appropriate light source, the 
photoactive group might react with the enzyme, via different intermediates, forming a covalent linkage with the amino acids 
proximal to the TSAO binding site. In both of these series of compounds, polymethylene linkers were used as spacers in order to 
obtain quite flexible molecules able to adopt the optimum conformation to interact with the enzyme.  
We were also interested in novel TSAO derivatives that may destabilize the RT by disrupting crucial interface interactions. We have 
previously seen that attachment of a hydroxypropyl substituent at the N-3 position of TSAO-T resulted in a two-fold better 
inhibition (TSAO-hp3T) than the prototype compound TSAO-T (Figure 1).21,23 This result is consistent with the prediction that an 
additional hydrogen bond could be formed with the protein backbone (Pro-B140). However, the improvement in activity was lower 
than expected and we reasoned that the putative extra hydrogen bond may be partially offset by the inherent flexibility of the 
methylene linker.21 With the aim to enhance the interaction of the N-3 substituent with HIV-1 RT we prepared a third series of 
compounds in which an unsaturated bond in the linker connecting the distal functional group (alcohol) with the N-3 position of the 
thymine has been introduced. The nature of the unsaturation may play an essential role in the relative orientation of the TSAO 
molecule and the terminal functional group. Therefore, compounds containing a cis- or trans- double bond into the linker were 
prepared. 
 
Results and discussion 
 
Chemical results 
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In order  to interact covalently with the amino acids of the HIV-1 RT close to the TSAO binding site, derivatives 2 and 3 bearing a 
bis-alkylating and epoxide moiety, respectively at the N-3 position (Scheme 1) have been prepared. Compound 2 was obtained in a 
68% yield by coupling the N-3 carboxylic acid TSAO derivative 123 with N,N-bis(2-chloro-ethyl)amine in the presence of BOP and 
triethylamine (Scheme 1). The N-3 epoxi derivative 3 could be readily prepared in one step following our previously described 
method for the selective N-3 alkylation of TSAO derivatives).13,23 Thus, treatment of TSAO-T (Scheme 1) with epibromohydrin in 
the presence of anhydrous potassium carbonate afforded the N-3-derivative 3 in 60% yield.  
 
 
 
Scheme 1. Synthesis of N-3 substituted TSAO derivatives 2 and 3 
 
In addition, a second series of compounds was prepared in which a photoactive group was attached at the N-3 position of TSAO-T 
(Scheme 2). Two different photoactive moieties, arylazide and benzophenone were chosen as they have been described as being 
among the most successful for labeling receptors and enzymes.24-26 Upon irradiation, these photoactivable groups produce 
extremely reactive species namely, a diradical, or a (singlet) nitrene for the benzophenone and arylazide, respectively24 that bind 
covalently to receptors and enzymes. Because it is essentially imposible to predict which group will be most readily reactive with 
the receptor, the use of different groups increases the likelihood of a successful covalent incorporation.  
As shown in Scheme 2, compound 5 which possesses an arylazide photophore, was synthesized in 85% yield by a method that 
consisted of coupling the previously described N-3 aminopropyl TSAO derivative 423 with 4-azidosalicylic acid27 in the presence 
of BOP and trietylamine. In a similar way, coupling of 4 with commercially available 4-benzoylbenzoic acid afforded 6 in 76 % 
yield.  
Finally, compounds with rigid side chains connecting a distal functional group (alcohol) with the N-3 position of TSAO-T by 
incorporating E or Z double bonds into the linker were prepared as follows. 
 
 
 
Scheme 2. Synthesis of N-3 substituted TSAO derivatives 5 and 6 
 
Synthesis of the ethoxycarbonylvinyl E isomer 7 was carried out following the procedure developed by Villarrasa et al28 that 
consisted on addition of the NH of a pyrimidine ring to the triple bond of an activated alkyne. Thus, when TSAO-T was treated with 
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ethyl propiolate and DMAP, in acetonitrile at room temperature, a quick reaction occurred to afford 7 in very good yield (82 %) 
(Scheme 3). Only one isomer, of E con
ppm, with JCH=CH 14.7 Hz).28-30 
For comparative purposes we were also interested in the synthesis of the corresponding Z isomer. Photochemical isomerization of 
an alkene of E configuration is a specially convenient route for the synthesis of the thermodynamically less stable Z isomer.31-33 
This method has been applied with success for the trans-cis isomerization of an ethoxycarbonylethyl moiety attached at the N-3 
position of a thymine.34 Based on these precedents we decided to carry out the photochemical isomerization of the E-isomer 7 to 
the corresponding Z-isomer 8. Due to the presence of other light-absorbing groups in the TSAO molecule, the reaction conditions 
were carefully adjusted to give a preponderance of the Z isomer without affecting to the other light-sensitive groups.  
Thus, by performing the UV difference spectra of TSAO-T and compound 7 one absorption maximum at 289 nm was detected that 
should correspond to the ethoxycarbonyl vinyl moiety (data not shown). This was the wavelength used for the UV irradiation in 
order to ensure that only the vinyl moiety was  affected and not the rest of the molecule. Thus, we irradiated with a medium-pressure 
mercury lamp a methanolic solution of the E isomer 7, and monitored the progress of the reaction by HPLC. After 30 min of 
irradiation with 290 nm light an equilibrium (1:1.5) mixture of E and Z isomers was observed. Prolonged reaction times (6h) did not 
affect the rate of isomerisation. It is interesting to note that no degradation and/or side reactions occurred in this photochemical 
trans-cis isomerisation. 
 
 
 
Scheme 3. Synthesis of N-3 substituted TSAO derivatives 7 - 10 
 
The 1HNMR spectrum of the mayor component 
and 6.70 ppm, with a vecinal coupling constant of JCH=CH 9.0 Hz as corresponds to a Z isomer.29,30 In addition, the 
stereochemistry of the double bond of 8 was unequivocally established as Z by NOE difference experiments. Thus, irradiation of 
ting 
that was the Z isomer.  
Finally, DIBAL-H (1M in THF) reduction of the carboxylic acid ester of 7 afforded the corresponding hydroxy methyl vinyl 
derivative 9 in 61 % yield (Scheme 3). A similar reaction with compound 8 gave 10 in 52% yield. 
 
Structures of the novel N-3 TSAO derivatives were assigned on the basis of their analytical and spectroscopic data. 
 
Biological results  
 
All the synthesized compounds showed pronounced inhibitory activity, in cell culture, against HIV-1 replication (EC50 = 0.04-0.75 
-2 (Table 1). There is a good agreement with the anti-HIV activities obtained in 
both MT-4 and CEM cell cultures.  
TSAO derivative 3 contained an epoxide moiety attached to the N-3 position showed, in cell culture, an anti-HIV-1 activity 
comparable to that of compound 2 with a bis-N-chloroethyl moiety at this position (Table 1). These groups could be introduced 
without apreciable loss of antiviral activity against the HIV-1 RT but did not improve activity, suggesting that although they were 
well-tolerated, they were not able to interact covalently with the enzyme.  
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The photoaffinity-labeled TSAO derivatives 5 and 6 were 3- to 10-fold less effective in comparison with TSAO-T (Table 1). 
However, they were at least 20-fold less cytostatic in cell culture than TSAO-T. Interestingly, the compounds showed marked 
activity against purified HIV-1 RT (IC50 ~ 2-fold lower than TSAO-T), (Table 1) which suggests that the loss of antiviral activity in 
cell culture may be due to pharmacokinetic considerations (uptake and/or metabolism). The potent inhibitory activity of 5 and 6 
against recombinant HIV-1 RT indicated that these compounds might be promising candidates for photoaffinity labeling 
experiments.  
 
The E-hydroxymethylvinyl derivative 9 was 10-fold more active in cell culture than the corresponding Z-isomer 10, and almost 
equally active than the prototype TSAO-hp3T (Table 1). With respect to the recombinant HIV-1 RT (Table 1), the E-isomer 9 
-
three-fold more active against HIV-1 RT than the Z-
observed in cell culture. Taken together, these data point to the impact of the relative orientation of the TSAO molecule and the 
terminal hydroxy group for an optimal interaction with the enzyme. Thus, the propyl linker, present in TSAO-hp3T, as well as the 
E-methylvinyl linker (present in 9) gave the most potent inhibitors while compound 10 with the Z-methylvinyl linker was 3-fold less 
active. These results indicated that the restricted Z-conformation may not allow the best interaction of the terminal OH with the 
HIV-1 RT. 
 
Table 1. Inhibitory effects of test compounds on HIV-1 and HIV-2 replication in MT-4 and CEM   cell culture and recombinant 
HIV-1 RT 
 
 EC50 (M)
a CC50 (M)
b IC50
c (µM) 
Comp. MT-4 CEM CEM  
 HIV-1 HIV-2 HIV-1 HIV-2 HIV1/138K  HIV-1 RT 
2 0.08  0.02 125 0.04  0.02 125 > 25 86 ± 30 8.2 ± 1.3 
3 0.11  0.11 50 0.10  0.02 50 > 10 47  16 2.4 ± 0.5 
5 0.68 0.33 50 0.37  0.25 50 > 50 250 0.4 ± 0.1 
6 0.29 0.12 50 0.16  0.09 50 > 50 250 0.5 ± 0.1 
9 0.04  0.0 2 0.05  0.03 2 > 2 3.4 1.9 0.5 ± 0.1 
10 0.32  0.02 25 0.12  0.0 25 > 5 44  7.8 1.6 ± 0.2 
TSAO-Td 0.06 0.03 20 0.06  0.01 20 > 10 12  3 1.0 ± 0.2 
TSAO-hp3Te 0.03 0.03 2 0.01 0.01 2 > 10 3.9  0.29 0.7 ± 0.1 
 
a 50% effective concentration, or the compound concentration required to inhibit HIV-induced cytopathicity by 50%.  
b 50% cytostatic concentration, or the compound concentration required to inhibit cell proliferation (CEM) or to reduce cell viability 
(MT-4) by 50%. 
c 50% inhibitory concentration, or the compound concentration required to inhibit recombinant HIV-1 RT     activity by 50%. 
d Data taken from ref  13. 
e Data taken from ref 23. 
 
Finally, the novel compounds were also evaluated for their inhibitory activity against a mutant HIV-1 strain that contains the E138K 
mutation in its RT which is known to afford pronounced resistance to TSAO-T.15 None of the compounds showed inhibitory 
activity against such mutant HIV-1/138K strain in CEM cell culture (Table 1) pointing to a similar mechanism of interaction of the 
compounds with HIV-1 RT as the prototype TSAO-T.  
 
Photochemical Kinetics  
Before attempting to use the arylazide 5 and benzophenone 6 TSAO derivatives for photoaffinity labeling, the effect of UV 
irradiation on the UV-vis spectrum was examined for both compounds. This was done both to demonstrate that the target 
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compounds could be photolyzed and to establish the optimal conditions (wavelength, power, irradiation time) required for biological 
testing. As shown in Figure 2, compound 5 (Figure 2A) has two absorption maxima at 268 and 309 nm while compound 6 (Figure 
2B) has only one absorption maximum at 260 nm. Photodecomposition of 5 and 6 was examined by monitoring the UV change of 
absorbance upon irradiation at different times.  
 
 
Fig. 2. Photodecomposition of arylazide derivative 5 (A) and the benzophenone derivative 6 (B). The spectra were taken at time 0 
(top line), and at the times indicated after photolysis at 254 nm. 
 
h 
using a higher power hand lamp for fixed periods of time (0.5-10 min). Large changes in the spectrum were seen over the whole 
ns 
previously mentioned (Figure 2B) resulted in only small spectral changes even after 10 minutes of irradiation.  
 
Results from Figure 3 show the spectral changes that occurred upon UV irradiation of 5 (Figure 3A) and 6 (Figure 3B) at 366 nm 
wavelenth using a lower power hand lamp for fixed periods of time. These spectral changes overall were similar to those that were 
observed for the photolysis at 254 nm, however, they were relatively smaller.  
It is well known that when irradiating at wavelengths of less that 280 nm, not only makes the reactive species unmasked, but 
photoinduced chemistry mediated by the protein itself starts to occur. This undesired effect, dictated by aromatic residues in the 
protein, can lead to damage of the protein and obscure results. For this reason although a great sensitivity to photolysis was observed 
at 254 nm, irradiation using wavelengths longer than 300 nm should be preferred in order to prevent the previously mentioned 
problem.35 
Taken together, these results indicated that 5 can be photolytically activated by UV ligth more efficiently than 6. Although a short 
wavelength UV-light (254 nm) allow the optimal photoactivation of 5 and 6 a long wavelength (>254 nm) should be preferable in 
order to prevent the damage of the protein.  
 
Effect of UV irradiation on the interaction of arylazide 5 and benzophenone 6 derivatives  with HIV-1 RT  
A preliminary study of the interaction of the photoaffinity analogues 5 and 6 with HIV-1 RT in the presence of UV light was carried 
out. Wild-type HIV-1 RT (200 nM) was incubated at room temperature with varying concentrations of 5 and 6 and then exposed to 
UV irradiation (312 nm) for varying times (30 s to 30 min). Following irradiation, RT was separated from unbound drug by passage 
through a Sephadex G-25 Quick Spin Protein Column (Roche). Thereafter, the RNA-dependent DNA polymerase activity of the 
enzyme was assessed and compared with the control reactions. These included a no drug control that was exposed to all 
experimental steps including irradiation, and a drug control which did not undergo UV exposure. Initial experiments demonstrated a 
marked loss of RT activity (5-10%) after 4 min. Complete loss of RT activity was observed at prolonged exposure times (20-30 
min), however this was attributable to UV damage and not to cross-linking of the TSAO derivative to RT. Analysis of the cross-
linking experiments that were carried out for shorter time periods demonstrated no discernable difference with the control reactions, 
which suggested that 5 and 6 were not effectively cross-linked with HIV-1 RT. Consistent with this result, the UV and CD spectra 
of enzymes that were subjected to UV irradiation were essentially identical to the control enzymes, confirming that compounds 5 
and 6 did not cross-link to RT. 
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Fig. 3. Photodecomposition of arylazide derivative 5 (A) and the benzophenone derivative 6 (B). The spectra were taken at time 0 
(top line), and at the times indicated after photolysis at 366 nm 
 
 
Experimental 
 
Synthesis 
Microanalyses were obtained with a Heraeus CHN-O-RAPID instrument. Electrospray mass spectra were measured on a quadropole 
mass spectrometer equippped with an electrospray source (Hewlett Packard, LC/MS HP 1100). 1H NMR spectra were recorded 
with a Varian Gemini, a Varian XL-300 and a Bruker AM-200 spectrometer operating at 300 and 200 MHz with Me4Si as internal 
standard. 13C NMR spectra were recorded with a Varian XL-300 and a Bruker AM-200 spectrometer operating at 75 MHz and at 
50 MHz with Me4Si as internal standard. Analytical thin-layer chromatography (TLC) was performed on silica gel 60 F254 
(Merck). Separations on silica gel were performed by preparative centrifugal circular thin-layer chromatography (CCTLC) on a 
ChromatotronR (Kiesegel 60 PF254 gipshaltig; Merck), layer thickness (1 mm), flow rate (5 mL min-1). Preparative layer 
chromatography was performed on 20 x 20 cm glass plates coated with a 2 mm layer of silica gel PF254 (Merck).  Analytical HPLC 
was carried out on a Wa
phase CH3CN/H2O (0.05%TFA). Flow rate: 1 ml/min. Detection: UV (254 nm). All retention times are quoted in minutes. 
Irradiations were carried out in a Pyrex cell (inmersion well) with light of 290 nm wavelenth using a medium-pressure mercury 
lamp. IR spectra were recorded with a Schimadzu IR-435 spectrometer.UV spectra were recorder with a Perkin Elmer Lambda 16 
Spectrophotometer.   
 
 
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[[N,N-bis(2-chloroethyl)carbamoyl]methyl]thymine]-3'-spiro-5"-
(4"-amino-1",2"-oxathiole-2",2"-dioxide) (2) 
To a cooled (-20ºC) solution of compound 123 (0.1 g, 0.16 mmol) and triethylamine (TEA) (0.04 mL, 0.32 mmol) in dry 
dichloromethane (4 mL) was added N,N-bis(2-chloro-ethyl)amine (0.03 g, 0.16 mmol). After 15 min, BOP (0.07 g, 0.16 mmol) was 
added. The mixture was stirred at room temperature overnight and then evaporated to dryness. The residue was dissolved in ethyl 
acetate (2 mL) and washed successively with 10 % citric acid (5 mL), 10 % NaHCO3 (5 mL) and brine (5 ml). The organic phase 
was dried (Na2SO4), filtered and evaporated to dryness. The residue was purified by CCTLC on the chromatotron (hexane: ethyl 
acetate, 2:1) to give 2 (0.07 g, 68%) as a white foam; (Found: C, 46.36; H, 6.28; N, 7.51. Calcd. for C30H52Cl2N4O9SSi2: C, 
-Bu), 1.95 (3H, s, CH3-5), 3.71 (4H, m, 
CH2Cl), 3.94 (4H, m, CH2N), 4.05 (1H, dd, H-5’a, J4’,5’a 3.8 Hz, J5’a,5’b 13.2 Hz), 4.13 (1H, dd, H-5’b, J4’,5’b 3.5 Hz ), 4.34 
(1H, t, H-4’), 4.80 (1H, d, H-2’), 4.89 (2H, d, CH2N, J 10.7 Hz), 5.74 (1H, s, H-3’’), 6.07 (1H, d, H-1’, J1’,2’ 8.0 Hz), 6.50 (2H, bs, 
NH2-4’’), 7.63 (1H, s, H- -5), 18.3, 18.9 [(CH3)3-C-Si], 25.5, 26.6 [(CH3)3-C-Si], 
44.2 (2 CH2Cl), 45.6 (NCH2), 49.5 (2 CH2N), 47.0 (CH2N), 49.1 (CH), 62.9 (C-5’), 75.3 (C-2’), 83.6 (C-4’), 88.7 (C-3’’), 93.4 (C-
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3’), 92.7 (C-1’), 111.1 (C-5), 134.9 (C-6), 151.5 (C-4’’), 151.9 (C-2), 163.1 (C-4), 163.9 (CON); m/z   (ESI; positive ion mode) 
771.4 (M+H+. C30H52Cl2N4O9SSi2 requires  770.24). 
 
 
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[2.3-epoxypropyl]thymine]-3'-spiro-5"-(4"-amino-1",2"-
oxathiole-2",2"-dioxide) (3)  
To a solution of TSAO-T13 (0.10 g, 0.17 mmol) in dry acetone (5 mL) was added dried and powdered K2CO3 (0.026 g, 0.19 mmol) 
and epibromohydrin (0.032 mL, 0.51 mmol). The reaction mixture was refluxed for 8 h and then concentrated to dryness. The 
residue was dissolved in ethyl acetate (20 mL), washed with brine (2 x 20 mL), dried (Na2SO4), filtered, evaporated to dryness and 
purified by CCTLC on the chromatotron (dichloromethane/ethyl acetate, 20:1) to give 3 (0.075 g, 60%) as a white, amorphous solid 
Me4Si] 0.81, 0.96 (18H, 2s, 2t-Bu), 1.95 (3H, s, CH3-5), 2.60 (1H, m, OCHa), 2.69 (1H, m, OCHb), 3.12 (1H, m, CH), 3.81 (1H, 
m, NCHa), 4.06 (1H, dd, H-5’a, J4’,5’a 4.1 Hz, J5’a,5’b 12.0 Hz), 4.11 (1H, dd, H-5’b, J4’,5’b 6.7 Hz), 4.26 (1H, m, NCHb), 4.35 
(1H, t, H-4’), 4.69 (1H, d, H-2’), 5.78 (1H, s, H-3’’), 6.11 (1H, d, H-1’, J1’,2’ 6.4 Hz), 6.57 (1H, bs, NH2-4’’), 7.56 (1H, s, H-6); 
-5), 18.2, 18.8 [(CH3)3-C-Si], 25.6, 26.4 [(CH3)3-C-Si], 43.5 (OCH2), 47.0 (CH2N), 
49.1 (CH), 62.5 (C-5’), 75.2 (C-2’), 83.9 (C-4’), 88.5 (C-3’’), 93.5 (C-3’), 92.5 (C-1’), 111.5 (C-5), 134.2 (C-6), 151.6 (C-4’’), 
151.7 (C-2), 163.4 (C-4); m/z (ESI; positive ion mode) 646.2 (M+H+. C27H47N3O9SSi2 requires 645.26).  
 
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[3-N’-(4-azidosalicylyl)aminopropyl]thymine]-3'-spiro-5"-(4"-
amino-1",2"-oxathiole-2",2"-dioxide) (5) 
To a solution of compound 423 (0.10 g, 0.16 mmol) in dry dichloromethane (10 mL) 4-azido salicylic acid (Husain et al., 1983)  
(0.034g, 0.19 mmol) and BOP  (0.070 g, 0.16 mmol) was added. After 15 min, triethylamine (TEA) (0.032 mL, 0.24 mmol) was 
added. The mixture was stirred at room temperature overnight and then evaporated to dryness. The residue was dissolved in ethyl 
acetate (2 mL) and washed successively with 10 % citric acid (10 mL), 10 % NaHCO3 (10 mL) and brine (10 ml). The organic 
phase was dried (Na2SO4), filtered and evaporated to dryness. The residue was purified by CCTLC on the chromatotron 
(dichloromethane: methanol, 50:1) to give 5 (0.11 g, 85%) as a white foam; (Found: C, 50.26; H, 6.48; N, 12.45. Calcd. for 
-1 cm-1 60600) and 309 (22000); 
- -Bu), 1.92 (2H, m, CH2CH2N), 1.94 
(3H, s, CH3-5), 3.42 (2H, m, CH2NHCO), 4.04 (2H, m, H-5’a, CH2N), 4.10 (1H, dd, H-5’b, J4’,5’b 3.6 Hz, J5’a,5’b 12.3 Hz), 4.33 
(1H, t, H-4’), 4.64 (1H, d, H-2’), 5.76 (1H, s, H-3’’), 6.10 (1H, d, H-1’, J1’,2’ 8.1 Hz), 6.43 (1H, bs, NH2-4’’), 6.54 (1H, s, Ph), 6.60 
(1H, d, Ph), 7.51 (1H, s, H- -5), 18.0, 18.6 
[(CH3)3-C-Si], 25.3, 26.0 [(CH3)3-C-Si], 28.9 (CH2), 37.0 (CH2NHCO), 39.4 (CH2N), 62.8 (C-5’), 75.1 (C-2’), 84.5 (C-4’), 87.1 
(C-3’’), 92.2 (C-3’), 92.3 (C-1’), 108.0 (CH-Ph), 110.1 (CH-Ph), 111.2 (C-5), 128.7 (CH-Ph), 134.2 (C-6), 145.9 (C-N3), 151.6 (C-
4’’), 151.6 (C-2), 163.3 (C-4), 163.3 (CONH); m/z (ESI; positive ion mode) 808.3 (M+H+. C34H53N7O10SSi2 requires  807.31). 
 
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[3-N’[(4-(benzoyl)-carbonylphenyl]aminopropyl]thymine]-3'-
spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (6) 
Following the previously described method, a solution of 423 (0.1 g. O.15 mmol), BOP (0.066 g, 0.15 mmol), 4-benzoylbenzoic 
acid (0.040 g, 0.18 mmol) and TEA (0.030 mL, 0.23 mmol) in dry dichloromethane was stirred at room temperature overnight and 
then evaporated to dryness. The residue was purified by CCTLC on the chromatotron (hexane:ethyl acetate, 1:1) to give 6 (0.097 g, 
-1 cm- s, 2t-Bu), 1.93 (2H, m, 
CH2CH2N), 1.95 (3H, s, CH3-5), 3.46 (2H, m, CH2NHCO), 4.10 (4H, m, H-5’a, CH2N), 4.34 (1H, t, H-4’), 4.66 (1H, d, H-2’), 
5.77 (1H, s, H-3’’), 6.12 (1H, d, H-1’, J1’,2’ 8.0 Hz), 6.47 (1H, bs, NH2-4’’), 7.51 (9H, m, Ph), H-6), 8.22 (1
MHz; (CD3)2CO; Me4Si] 12.8 (CH3-5), 18.1, 18.6 [(CH3)3-C-Si], 25.0, 26.3 [(CH3)3-C-Si], 29.1 (CH2), 37.4 (CH2NHCO), 39.5 
(CH2N), 62.8 (C-5’), 75.1 (C-2’), 84.9 (C-4’), 87.3 (C-3’’), 92.1 (C-1’), 92.3 (C-3’), 112.5 (C-5), 130.0, 130.2, 129.0, 127.6 (Ph), 
134.3 (C-6), 137.9, 138.9, 140.3 (C-Ph), 151.7 (C-4’’), 151.8 (C-2), 163.3 (C-4), 166.0 (CONH), 195.8 (PhCOPh). m/z (ESI; 
positive ion mode) 855.5 (M+H+ C41H58N4O10SSi2 requires  854.34). 
 
[1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[(E)-2-ethoxycarbonylvinyl]thymine]-3'-spiro-5"-(4"-amino-1",2"-
oxathiole-2",2"-dioxide) (7) 
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A mixture of TSAO-T13 (0.4 g, 0.68 mmol), ethyl propiolate (0.082 mL, 0.84 mmol) and 4-(dimethylamino)pyridine (DMAP) 
(0.102 g, 0.84 mmol) was stirred at room temperature for 1.5 h. Solvent was evaporated to dryness and the residue was dissolved in 
ethyl a
The organic phase was dried (Na2SO4), filtered, evaporated to dryness and purified by CCTLC on the chromatotron (hexane:ethyl 
acetate, 2:1) to give 7 (0.39 g, 82%) as a white foam; (Found: C, 50.30; H, 7.45; N, 6.85. Calcd. for C29H49N3O10SSi2: C, 50.63; 
2s, 2t-Bu), 1.27 (3H, t, OCH2CH3, J 7.0 Hz), 1.98 (3H, s, CH3-5), 4.06 (1H, dd, H-5’a, J4’,5’a 3.4 Hz, J5’a,5’b 12.2 Hz), 4.12 (1H, 
dd, H-5’b, J4’,5’b 3.6 Hz), 4.20 (2H, q, OCH2CH3), 4.39 (1H, t, H-4’), 4.65 (1H, d, H-2’), 5.78 (1H, s, H-3’’), 6.13 (H-1’, d, 1H, 
J1’,2’ 8.1 Hz), 6.45 (2H, bs, NH2-4’’), 6.99 (1H, d, NCH=CH), 7.56 (1H, s, H-
(CD3)2CO; Me4Si] 13.2 (CH3-5), 14.5 (OCH2CH3), 18.1, 18.6 [(CH3)3-C-Si], 25.0, 26.3 [(CH3)3-C-Si], 61.0 (OCH2), 63.1 (C-
5’), 75.5 (C-2’), 85.5 (C-4’), 87.6 (C-3’’), 92.7 (C-1’, C-3’), 111.4 (C-5), 113.8 (NCH=CH), 134.8 (C-6), 135.3 (NCH=CH), 151.7 
(C-4’’), 150.9 (C-2), 162.3 (C-4), 167.4 (CO). m/z (ESI; positive ion mode) 688.4 (M+H+ C29H49N3O10SSi2 requires  687.29). 
  
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[(Z)-2-ethoxycarbonylvinyl]thymine]-3'-spiro-5"-(4"-amino-
1",2"-oxathiole-2",2"-dioxide) (8) 
A solution of the E isomer 7 (0.100 g, 0.14 mmol) in methanol (100 mL) in a Pyrex cell (inmersion well) was irradiated under argon 
atmosphere at room temperature with light of 290 nm wavelenth using a medium-pressure mercury lamp. The progress of the 
reaction was monitored by HPLC. After 30 min of irradiation an equilibrium (1:1.5) mixture of E and Z isomers were obtained. 
Prolonged reaction times (6h) did not affect to the composition of the mixture. Solvent was evaporated under reduced pressure to 
give a residue which were purified by preparative thin layer chromatography using as eluent (dichloromethane:ethyl acetate, 40:1). 
After several developments two different moving bands were separated. 
From the fastest moving band E isomer 7 (0.040 g, 40%) was isolated. 
From the slowest moving band Z isomer 8 (0.060 g, 60%) was isolated; (Found: C, 50.30; H, 7.45; N, 6.85. Calcd. for 
C29H
-Bu), 1.17 (3H, t, OCH2CH3, J 5.2 Hz), 1.93 (s, 3H, CH3-5), 4.05 (1H, dd, H-5’a, 
J4’,5’a  4.1 Hz, J5’a,5’b 11.4 Hz), 4.09 (q, 2H, OCH2CH3), 4.10 (1H, dd, H-5’b, J4’,5’b 3.5 Hz ), 4.31 (t, 1H, H-4’), 4.70 (1H, d, 
H-2’), 5.75 (1H, s, H-3’’), 6.01 (1H, d, H-1’, J1’,2’ 7.9 Hz), 6.12 (d, 1H, NCH=CH), 6.47 (bs, 1H, NH2-4’’), 6.70 (d, 1H, 
NCH=CH, J 9.0 Hz), 7.55 (s, 1H, H-6). (ESI; positive ion mode)  688.4 (M+H+ C29H49N3O10SSi2 requires  687.29). 
 
 
 [1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[(E)-3-hydroxy-1-propenyl]thymine]-3'-spiro-5"-(4"-amino-1",2"-
oxathiole-2",2"-dioxide) (9) 
DIBAL-H (1 M solution in THF, 0.28 mL, 0.28 mmol) was added dropwise into a solution of 7 (0.2 g, 0.29 mmol) in dry THF (0.5 
mL) at 0ºC over 10 min with stirring under argon. After the reaction mixture was allowed to reach room temperature, stirring was 
continued for 3 h. Saturated aqueous NH4Cl (0.5 mL) was then added, and the gel-like solid was filtered off using a Celite bed. 
Evaporation of the solvent gave a residue that was purified by CCTLC on the chromatotron using hexane/ethyl acetate (2:1) to give 
9 (0.11 g, 61%) as a white foam; (Found: C, 50.50; H, 7.85; N, 6.75. Calcd. for C27H47N3O9SSi2: C, 50.21; H, 7.33; N, 6.51%). 
-Bu), 1.96 (3H, s, CH3-5), 4.05 (1H, dd, H-5’a, J4’,5’a 3.7 Hz, J5’a,5’b 
12.2 Hz), 4.13 (1H, dd, H-5’b, J4’,5’b 3.5 Hz ), 4.16 (1H, t, OH, J 5.8 Hz), 4.23 (2H, m, CH2OH), 4.36 (1H, t, H-4’), 4.65 (1H, d, 
H-2’), 5.78 (1H, s, H-3’’), 6.12 (1H, d, H-1’, J1’,2’ 8.2 Hz), 6.50 (1H, bs, NH2-4’’), 6.56 (1H, m, NCH=CH), 6.82 (1H, m, 
NCH=CH, J 14.4 Hz), 7.52 (s, 1H, H- -5), 18.1, 18.6 [(CH3)3-C-Si], 25.0, 26.3 
[(CH3)3-C-Si], 61.7 (CH2OH), 63.5 (C-5’), 75.1 (C-2’), 85.9 (C-4’), 87.2 (C-3’’), 92.8 (C-1’, C-3’), 111.6 (C-5), 123.4 (CH=CH), 
130.3 (NCH=CH), 134.6 (C-6), 151.4 (C-4’’), 150.6 (C-2), 162.5 (C-4). (ESI; positive ion mode)  646.6 (M+H+ C27H47N3O9SSi2 
requires  645.26). 
 
 
[1-[2',5'-Bis-O-(tert-butyldimethylsilyl)- -D-ribofuranosyl]-3-N-[(Z)-3-hydroxy-1-propenyl]thymine]-3'-spiro-5"-(4"-amino-1",2"-
oxathiole-2",2"-dioxide) (10) 
Following the previosly described method for the synthesis of 9, a solution of 8 (0.050 g, 0.07 mmol) in dry THF (0.25 mL) was 
treated with DIBAL-H (1 M solution in THF, 0.14 mL, 0.14 mmol). Purification of the residue by CCTLC on the chromatotron 
using hexane/ethyl acetate (2:1) afforded 10 (0.058 g, 52%) as a white foam; (Found: C, 50.50; H, 7.85; N, 6.75. Calcd. for  
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-Bu), 1.94 (3H, s, 
CH3-5), 3.64 (1H, t, OH, J = 5.8 Hz), 3.92 (2H, t, CH2OH), 4.04 (1H, dd, H-5’a, J4’,5’a 3.8 Hz, J5’a,5’b 12.3 Hz), 4.12 (1H, dd, H-
5’b, J4’,5’b 3.4 Hz ), 4.32 (1H, t, H-4’), 4.69 (1H, d, H-2’), 5.74 (1H, s, H-3’’), 5.89 (1H, m, NCH=CH), 6.05 (1H, d, H-1’, J1’,2’ 
8.0 Hz), 6.09 (m, 1H, NCH=CH, J 9.5 Hz),  6.45 (bs, 1H, NH2-4’’), 7.55 (s, 1H, H-6). (ESI; positive ion mode)  646.6 (M+H+ 
C27H47N3O9SSi2 requires  645.26). 
 
 
Biological Methods  
 
Cells and Viruses  
Human immunodeficiency virus type 1 [HIV-1 (IIIB)] was obtained from Dr. R.C. Gallo (when at the National Cancer Institute, 
Bethesda, MD). HIV-2 (ROD) was provided by Dr. L. Montagnier (when at the Pasteur Institute, Paris, France). 
 
Activity Assay of Test Compounds against HIV-1 and HIV-2 in CEM and MT-4 Cell Cultures  
A total number of 4 x 106 CEM or 3 x 105 MT-4 cells per milliliter were infected with HIV-1 (IIIB ) or HIV-2 (ROD) or HIV-
1/138K (a virus strain that was selected in the presence of TSAO-m3T and that contained the E138K mutation in its RT) at ~ 100 
CCID50 (50% cell culture infective dose) per milliliter of cell suspension. Then an amount of 100 µL of the infected cell suspension 
was transferred to microtiter plate wells and mixed with 100 µL of the appropriate dilutions of the test compounds. Syncytia 
formation (CEM) or HIV-induced cytopathicity (MT-4) was recorded microscopically (CEM) or by trypan blue dye exclusion (MT-
4) in the HIV-infected cell cultures after 4 days (CEM) or 5 days (MT-4). The 50% effective concentration (EC50) of the test 
compounds was defined as the compound concentration required to inhibit virus-induced cytopathicity (CEM) or to reduce cell 
viability (MT-4) by 50%. The 50% cytostatic or cytotoxic concentration (CC50) was defined as the compound concentration 
required to inhibit CEM cell proliferation by 50% or to reduce the number of viable MT-4 cells in mock-infected cell cultures by 
50%. 
 
Inhibitory Effect of Test Compounds against Recombinant HIV-1 RT  
HIV-1 RT was purified as described previously).36,37 Inhibition of the RNA-dependent DNA polymerase activity of HIV-1 RT 
was assessed using a fixed time scintillation proximity assay. Briefly, reactions were carried out in 50mM Tris-HCl pH 7.8 (37°C), 
50mM KCl, 1mM MgCl2 and contained 700nM of poly(rA)-oligo(dT)18 (the oligo(dT)18 was synthesized with a biotin moiety on 
the 5’- ble concentrations of ligand dissolved in DMSO (3% final concentration). Reactions were 
initiated by the addition of 20 nM of wild-type or E138K HIV-1 RT and incubated for 20 min at 37 °C.  Reactions were quenched 
by addition of 0.5 mg/ml scintillant impregnated streptavidin coated polyvinyltoluene beads (Amersham) in a quench solution 
containing 100 mM EDTA. Plates were allowed to rest for 2 hrs prior to counting radioactivity using a Hewlett-Packard plate 
reader. The 50% inhibitory concentration (IC50) was defined as the concentration of the compound required to inhibit enzyme 
activity by 50%. 
 
Photoaffinity cross-linking experiments  
200 nM wild-type HIV-1 RT was incubat
-HCl pH 7.8, 50 mM KCl, and 1mM MgCl2. The reaction mixtures were then irradiated with a hand-held  UV lamp 
(Fisher Biotech) at 312 nm wavelength with an intensity of 1.15 mW/cm2 for varying times (30 s to 30 min).  
Following irradiation, RT was separated from unbound drug by passage through a Sephadex G-25 Quick Spin Protein Column 
(Roche). Thereafter, the RNA-dependent DNA polymerase activity of the enzyme was assessed as described above. Control 
reactions included no inhibitor (and in this case they were subjected to UV irradiation) or inhibitor (without exposure to UV 
irradiation). 
In addition to the activity assays described above, the RT that was subjected to UV irradiation was also assessed by ultraviolet (UV) 
absorption and circular dichroism (CD) spectroscopy. The UV absorption spectroscopy was carried out using a Beckman Coulter 
DU530 UV/VIS spectrophotometer. CD spectra were collected at ambient room temperature (24 oC) using an Aviv Instruments CD 
Spectrometer (Model 202). 
 
Conclusions 
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As shown above, all the compounds showed pronounced activity against HIV-1 replication in cell culture. The most antivirally 
active compounds were the E-hydroxymethylvinyl 9 and the bis-N-chloroethyl 2 derivatives.  
The alkylating moieties (epoxide and nitrogen mustard) introduced at the N-3 position of TSAO-T were tolerated without loss of 
activity but they did not improve activity.  
On the other hand, presence of an alcohol functional group linked to the N-3 position of thymine has a significant impact on the 
activity provided that this moiety was linked to this position through a flexible polymethylene linker or a trans  double bond. 
Benzophenone and arylazide containing TSAO analogues derivatives were synthetically accesible. Before attempting to use these 
analogues for photoaffinity labeling, we have first established that the presence of the photophore in the side chain is well tolerated 
without a significant loss of activity. The arylazide analogue 5 was more efficiently photolyzed than the benzophenone derivative 6. 
A preliminary study of the interaction of the photoaffinity analogs 5 and 6 with HIV-1 RT in the presence of UV light was carried 
out, however successful cross-linking to the target protein was not obtained. Although we were unable to cross-link the current 
compounds to HIV-1 RT, our studies demonstrated that the cross-linking approach is feasible in that photoaffinity labels can be 
introduced on the N-3 of TSAO without apreciable loss of inhibitory activity. The future challenge is to alter the orientation and/or 
length of the spacer or to include different moieties at the molecule to identify a TSAO derivative that can cross-link to RT. 
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